References
- GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;385(9963):117–171.
- Thun MJ, Carter BD, Feskanich D, et al. 50-year trends in smoking-related mortality in the United States. N Engl J Med. 2013;368(4):351–364.
- Islami F, Torre LA, Jemal A. Global trends of lung cancer mortality and smoking prevalence. Transl Lung Cancer Res. 2015;4(4):327–338.
- Robert Koch Institut. German Centre for Cancer Registry Data. 2015 [ cited 2015 Dec 10]. Available from: http://www.krebsdaten.de/Krebs/DE/Datenbankabfrage/datenbankabfrage_stufe1_node.html
- European Respiratory Society (ERS). European Lung White book. 2015 [ cited 2015 Dec 10]. Available from: http://www.erswhitebook.org/chapters/the-economic-burden-of-lung-disease/
- Gesundheitsberichterstattung des Bundes (GBE). Health situation, death rates, mortality, and causes of death (in German). [ cited 2015 Dec 10]. Available from: http://www.gbe-bund.de/
- Denman AR, Rogers S, Timson K, et al. Future initiatives to reduce lung cancer incidence in the United Kingdom: smoking cessation, radon remediation and the impact of social change. Perspect Public Health. 2015;135(2):92–101.
- Schwarzkopf L, Wacker M, Holle R, et al. Cost-components of lung cancer care within the first three years after initial diagnosis in context of different treatment regimens. Lung Cancer. 2015;90(2):274–280.
- National Lung Screening Trial Research Team. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011;365(5):395–409.
- Hense HW. Screening for lung cancer: balancing hope with doubt about applicability. Dtsch Arztebl Int. 2015;112(38):635–636.
- Puggina A, Broumas A, Ricciardi W, et al.. Cost-effectiveness of screening for lung cancer with low-dose computed tomography: a systematic literature review. Eur J Public Health. 2016;26(1):168–175.
- Roth JA, Sullivan SD, Goulart BH, et al. Projected clinical, resource use, and fiscal impacts of implementing low-dose computed tomography lung cancer screening in Medicare. J Oncol Pract. 2015;11(4):267–272.
- Gendarme S, Perrot E, Reskot F, et al.. [Economic impact of lung cancer screening in France: A modeling study]. Rev Mal Respir. 2015;pii: S0761-8425(15)00367-8. doi:10.1016/j.rmr.2015.10.004. [Epub ahead of print]
- Gemeinsamer Bundesausschuss (G-BA). Early benefit assessment data base. 2015[ cited 2015 Dec 10]. Available from: https://www.g-ba.de/informationen/nutzenbewertung/
- Sullivan R, Peppercorn J, Sikora K, et al. Delivering affordable cancer care in high-income countries. Lancet Oncol. 2011;12(10):933–980.
- Kutikova L, Bowman L, Chang S, et al. The economic burden of lung cancer and the associated costs of treatment failure in the United States. Lung Cancer. 2005;50(2):143–154.
- Vogl M, Leidl R. Informing management on the future structure of hospital care: an extrapolation of trends in demand and costs in lung diseases. Eur J Health Econ. 2015. [Epub ahead of print]
- Ansmann L, Nitzsche A, Neumann M. Niedergelassene Hämatologen und Onkologen: Gestresst, aber zumeist zufrieden. Dtsch Arztebl. 2014;111(7):262–264.
- Davis KL, Goyal RK, Able SL, et al. Real-world treatment patterns and costs in a US Medicare population with metastatic squamous non-small cell lung cancer. Lung Cancer. 2015;87(2):176–185.
- Kapo JM, Akgun KM. Integrating palliative care into the care of patients with advanced lung cancer. Cancer J. 2015;21(5):434–439.